Plasma GLP1 and Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention
The Association of Plasma Levels of GLP1 With Prognosis of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention
1 other identifier
observational
200
1 country
1
Brief Summary
The purpose of this study is to evaluate the predicting role of plasma GLP1 level on major adverse cardiovascular events (MACE) in patients with acute myocardial infarction who undergo percutaneous coronary intervention.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2016
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2016
CompletedFirst Submitted
Initial submission to the registry
April 12, 2016
CompletedFirst Posted
Study publicly available on registry
July 27, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2017
CompletedJuly 27, 2016
July 1, 2016
1.7 years
April 12, 2016
July 26, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
major adverse cardiovascular events (MACE) after 6 months
at 6 months
Secondary Outcomes (1)
left ventricular ejection fractions
at 3 months
Eligibility Criteria
patients with AMI who were admitted to the Chinese PLA General Hospital for pPCI
You may qualify if:
- Patients were eligible if they were 18 years or older and presented within 12 h from the onset of symptoms and signs of acute myocardial infarction to the catheterization laboratory.
You may not qualify if:
- Taking drugs of GLP-1 analogue and DPP4 inhibitor
- Cancer patients
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Li Jing-Wei
Beijing, Beijing Municipality, 100853, China
Related Publications (3)
Chen WR, Hu SY, Chen YD, Zhang Y, Qian G, Wang J, Yang JJ, Wang ZF, Tian F, Ning QX. Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J. 2015 Nov;170(5):845-54. doi: 10.1016/j.ahj.2015.07.014. Epub 2015 Jul 26.
PMID: 26542491BACKGROUNDChen WR, Shen XQ, Zhang Y, Chen YD, Hu SY, Qian G, Wang J, Yang JJ, Wang ZF, Tian F. Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction. Endocrine. 2016 Jun;52(3):516-26. doi: 10.1007/s12020-015-0798-0. Epub 2015 Nov 16.
PMID: 26573925BACKGROUNDChen WR, Tian F, Chen YD, Wang J, Yang JJ, Wang ZF, Da Wang J, Ning QX. Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction. Int J Cardiol. 2016 Apr 1;208:109-14. doi: 10.1016/j.ijcard.2015.12.009. Epub 2015 Dec 15.
PMID: 26849684BACKGROUND
Study Officials
- PRINCIPAL INVESTIGATOR
Yun Dai Chen, M.D
Chinese PLA General Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, Dr.
Study Record Dates
First Submitted
April 12, 2016
First Posted
July 27, 2016
Study Start
April 1, 2016
Primary Completion
December 1, 2017
Study Completion
December 1, 2017
Last Updated
July 27, 2016
Record last verified: 2016-07